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Key points
• Finding an inherited
complement abnormal-
ity in HSCT-associated
TMA provides a ratio-
nale for the use of a
complement inhibitor.
• Alternative complement
inhibitors such as Cov-
ersin should be consid-
ered in patients who are
resistant to eculizumab.
Introduction
Thrombotic microangiopathy (TMA) is a well-recognized complication of hematopoietic stem cell
transplantation (HSCT).1 The incidence ranges from 10% to 30%2 with a poor outcome with proteinuria
and complement activation.3 Complement abnormalities identified include factor H autoantibodies and a
high prevalence of a deletion that includes the genes encoding factor H–related proteins 1 and 3.4 The
involvement of complement in the pathogenesis of HSCT-TMA has led to the use of eculizumab to treat
HSCT-TMA5 with evidence of improved survival.6 The dose needed to achieve complement blockade is
higher than in atypical hemolytic uremic syndrome (aHUS).5-7 Eculizumab is also used to treat parox-
ysmal nocturnal hemoglobinuria (PNH), and resistance has been reported in Japanese patients carrying
a C5 variant (c.2654G.A; p.Arg885His) that prevents eculizumab binding.8 This variant is found in the
Japanese population at an allele frequency of 1.7%. We report here a patient with HSCT-associated
TMA resistant to eculizumab who was found to carry a CFH variant known to be associated with aHUS
and the C5 variant (c.2654G.A; p.Arg885His). Because of this, the patient was treated with the
recombinant C5 inhibitor Ornithodoros moubata complement inhibitor (Coversin).9
Case description and methods
A male child presented at 1 year with a cervical lymph node abscess and recurrent cervical
lymphadenopathy, biopsy of which showed granulomatous inflammation. At 20 months, he was found to
have liver abscesses and a middle lobe mass of the right lung. On biopsy, these showed granulomas with
necrosis and fibrosis (Figure 1A). A nonreactive nitroblue tetrazolium test suggested a diagnosis of
chronic granulomatous disease. Screening of the gene (CYBB) encoding cytochrome b(2245)b
subunit showed a deletion of exon 4. At the age of 3 years, he underwent an HLA-matched unrelated
HSCT. A timeline is shown in Figure 2A. At day127 (D127), he developed skin graft-versus-host
disease (GVHD), which was treated with topical steroids. At D136, he developed gastrointestinal (GI)
GVHD, which was treated with methylprednisolone and infliximab. He also developed features of HSCT-
TMA with microangiopathic hemolytic anemia (MAHA) and hypertension; cyclosporin was withdrawn
with improvement. ADAMTS13 activity was 40%. The diarrhea subsided and was replaced by an ileus
with recurrent melena. Abdominal computed tomographic scan at D182 showed thickening of the small
bowel (supplemental Figure 1). Upper and lower GI biopsies undertaken by endoscopy showed
hyperplastic and regenerative changes in the antrum and duodenum that were not typical of GVHD, and
there was no histological evidence for adenovirus or cytomegalovirus. At D1132, he developed seizures
with hypertension. Peripheral blood film showed fragmentation. Lactate dehydrogenase (LDH) was
elevated (1819 IU/L, normal range 470-900 IU/L); platelet count was decreased (75 3 109/L), and
hemoglobin was decreased (8.2 g/dL). Recurrent TMA was diagnosed,10 and eculizumab was started at
600 mg IV weekly. Despite ongoing treatment of GVHD (with more frequent infliximab doses, further
pulses of high-dose steroids, basiliximab, and mesenchymal stem cells), he developed a skin rash, which
on biopsy suggested grade II skin GVHD (Figure 1B). Repeat GI endoscopies (D1196) for the first time
showed GVHD (grade IV) (Figure 1C). Although the rash improved, the GI problems persisted. After
10 weekly infusions of eculizumab with no clinical improvement, mutation screening (of DNA samples
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extracted prior to HSCT) showed a functionally significant11
heterozygous CFH mutation (c.3356A.G; p.Asp1119Gly) pre-
viously found in familial aHUS.12 In addition, he carried the C5
variant (c.2654G.A; p.Arg885His) that confers resistance to
eculizumab.8 Factor H autoantibodies were not detected. Multiplex
ligation-dependent probe amplification showed 2 copies of CHFR1
and CFHR3. Screening of parental samples showed that he had
inherited the CFH and the C5 variant from his father, who has no
medical problems. Classical pathway hemolytic assay (CH50) while
he was on eculizumab at D1145 and D1160 was 35% and 33% of
normal, respectively.
To determine whether C5 could be blocked by Coversin, ascending
doses of eculizumab and Coversin were added to patient serum
and pooled control serum. Terminal pathway activity was assessed
by measurement of CH50 (Quidel, San Diego, CA). Coversin at
;15 mg/mL, the known therapeutic concentration, completely
blocked terminal complement activity (TCA) in both patient and
control serum (Figure 2B). In contrast, eculizumab 50 mg/mL ab-
lated TCA in control serum but was unable to completely inhibit
TCA at any concentration tested in patient serum.
A request was made to Akari Therapeutics PLC for Coversin.
Following parental consent, Akari supplied Coversin, and eculizu-
mab was discontinued.
The quantity of Coversin available was limited; treatment was
commenced on D1214 with a blocking subcutaneous dose of
0.57 mg/kg (7.63 mg) and thereafter a daily maintenance dose of
28% of this (2.18 mg) for the next 10 days until D1224. The initial
clinical response was encouraging with an improvement in his GI
symptoms with a decrease in the volume of diarrhea and resolution
of melena. After D1224, the frequency was decreased to alternate
days to conserve the supply. Twelve doses of 2.18 mg were given
on alternate days until D1248. CH50 assays showed that despite
the clinical improvement blockade of TCA was not complete on
alternate day administration (Figure 2C). A further dose of 7.63 mg
Coversin was therefore given on D1250 followed by 2.18 mg daily
for 6 days at which time no further Coversin was available. With this,
the CH50 decreased to beneath the lower limit of normal of 70
equivalent units per milliliter (CH50 UEq/mL). Over the next 21
days, the patient’s condition deteriorated, and he died on D1277.
At postmortem, there was evidence of severe pulmonary arterial
vasculopathy (Figure 1D-E). There was hemorrhagic necrosis of the
small bowel with arterial fibrinoid necrosis and intraluminal thrombi
resultant from TMA (Figure 1F-H). Because of autolysis, it was not
possible to determine whether there was a renal TMA. The lowest
estimated glomerular filtration rate estimated using the “bedside”
Schwartz equation13 was 38 mL/min/1.73 m2 on D1270. During
the 58 days that the patient received Coversin, there were no
adverse events and no injection site reactions. Low-titer non-
neutralizing anti-Coversin antibodies (immunoglobulin G) were
detected after 14 days of treatment. LDH levels and reticulocyte
count during the period of time that the patient received both
eculizumab and Coversin are shown in Figure 2D. Research within
the report was approved by the North East–York Research Ethics
Committee and performed in accordance with the Declaration of
Helsinki.
A B C D
E F G H
Figure 1. Histopathology. (A) Preserved liver parenchyma with an inflammatory focus within the lobule, associated with clusters of foamy macrophages containing finely
granular golden brown pigment, which was positive with PAS stain and negative with Perls stain for iron. These appearances are characteristic of chronic granulomatous
disease (hematoxylin and eosin [H&E] stain). (B) Skin biopsy demonstrating spongiosis of the epidermis with basal vacuolization, dyskeratosis, and a lymphocytic infiltrate of the
papillary dermis. Pigment incontinence is also seen within the papillary dermis. These features are consistent with GVHD (H&E stain). (C) Bowel mucosa with crypts shows
intraepithelial vacuoles, filled with karyorrhectic debris. These apoptotic bodies are numerous, and intraepithelial lymphocytes are also present. There is scant inflammation
within the lamina propria. These features are consistent with GVHD (H&E stain). (D) Postmortem lung parenchyma with muscular arteries shows concentric cellular intimal
proliferation. There is almost complete occlusion. Within the airspaces, there is degenerating fibrin. No acute inflammation was present (H&E stain). (E) The corresponding elastic
Van Gieson stain of panel D confirms the concentric intimal proliferation. These findings are of severe pulmonary arterial vasculopathy (EVG stain). (F) Postmortem bowel,
with extensive necrosis and loss of the normal mucosa. Bacterial colonies are seen, and even at this low power, hemorrhage can be appreciated within the submucosa, which also
appears expanded and fibrotic. The muscularis propria appears ragged. These features are of hemorrhagic necrosis, resultant from TMA (H&E stain). (G-H) A high-power view
of the submucosa from panel F, highlighting a vessel with eccentric partial occlusion due to thrombus adherent to the wall. A similar vessel is seen in panel H, which is
occluded and contains macrophages. These features are related to the underlying vasculopathy (H&E stain). Scale bars, 500 mm (A) and 100 mm (B-H).
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Results and discussion
TMA is a well-established complication of HSCT.14 Pivotal to all
forms of TMA is endothelial cell activation15; multiple factors, in-
cluding infections, drugs, and GVHD, are likely responsible in
HSCT-TMA. There is interest in the role of complement in all forms
of TMA, including HSCT, driven by the finding of complement
abnormalities in;50% of aHUS patients. The improved outcome in
aHUS with eculizumab7 has led to enthusiasm for its use in other
forms of TMA. That complement activation should be seen in TMA is
not surprising in view of the interaction of the complement and
coagulation pathways.16 In such circumstances, complement block-
ade with agents such as eculizumab may only be appropriate if
factors are present that lead to impaired regulation of complement
activation. Are such abnormalities present in HSCT-TMA? In 3 of 6
patients with HSCT-TMA, Jodele et al identified factor H autoanti-
bodies.4 An association between factor H autoantibodies and aHUS
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Figure 2. Timeline and effects of Coversin. (A) Timeline of events including GVHD and MAHA. (B) Effect of increasing concentrations of Coversin and eculizumab
on CH50 in patient and normal control serum. (C) CH50 during treatment with alternate day and daily Coversin. (D) LDH levels (U/L) and reticulocyte count (103/mm3)
during treatment with eculizumab and Coversin. Shaded areas in the boxes showing the duration of Coversin therapy indicate where daily therapy was given, and unshaded
areas in the boxes indicate where alternate day therapy was given.
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HSCT-TMA had a heterozygous deletion, including CFHR1.4 In
our patient, we found a functionally significant CFH mutation
(c.3356A.G; p.Asp1119Gly).11 Use of eculizumab was therefore
appropriate. Because of the lack of response, we looked for factors
that might be impairing the activity of the drug. Finding theC5 variant
that confers eculizumab resistance was unexpected and led us to
seek alternative agents to block C5.
Coversin is a 16.7-kDa recombinant protein derived from a natural
protein discovered in the saliva of theOrnithodorosmoubata tick.18 In
vitro assays suggested that complement blockade could be achieved
with Coversin. The crystal structure of Coversin bound to C5 indi-
cates that Arg885His would not inhibit binding of the drug.19 When
Coversin enters the circulation, it binds rapidly to circulating C5.
Once bound, it assumes the half-life of C5, which in humans is
reported to be 63 hours.20 Any free Coversin that is not bound to C5
is rapidly excreted by the kidney because of its low molecular weight.
Experiments in C5-deficient mice show that virtually no Coversin can
be detected within 30 minutes of IV administration.9 C5 is rapidly
synthesized by the liver and other tissues and in the absence of any
circulating Coversin will restore hemolytic activity in humans within
;24 hours of administration of Coversin.
To assess the response to eculizumab and Coversin, we used
both the clinical status and the markers of MAHA. The clinical
response and improvement in LDH and reticulocyte count suggest
that introduction of Coversin was beneficial. However, the supply
of Coversin was limited, leaving a small window of opportunity to
reverse the TMA. Despite the eventual outcome, this unique case
provides proof of principle that alternative C5 inhibitors may be as
effective as eculizumab in patients with inherited forms of complement
dysregulation. Coversin may have a particular role in those patients
who are resistant to eculizumab due to C5 variants such as
c.2654G.A; p.Arg885His.
The previous finding of factor H autoantibodies and now in our
patient a functionally significant CFH mutation does suggest
that some patients with HSCT-TMA will have an underlying
complement abnormality. In larger cohorts of HSCT-TMA
patients, the prevalence of such abnormalities has been found
to be higher,21 emphasizing the potential role for complement
inhibitors.
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